Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2756230 | 0.82 | PTGDR2 (0.44) | ALDH1A1HPGDPTGDR2MAPTKDM4E | |
| SCHEMBL8291391 | 0.77 | MEN1 (0.76) | ALDH1A1HPGDMEN1KMT2APTGDR2 | |
| SCHEMBL11563601 | 0.76 | ALDH1A1 (0.72) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL8202114 | 0.76 | ALDH1A1 (0.96) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL201690 | 0.73 | ALDH1A1 (0.68) | ALDH1A1HPGDMEN1KMT2APTGDR2 | |
| SCHEMBL791811 | 0.73 | PTGS2 (0.49) | ALDH1A1HPGDMEN1KMT2APTGDR2 | |
| SCHEMBL791528 | 0.73 | PTGDR2 (0.61) | ALDH1A1HPGDMEN1KMT2APTGDR2 | |
| SCHEMBL13675569 | 0.72 | ALOX5 (0.52) | ALDH1A1PTGDR2MAPTKDM4EPOLB | |
| SCHEMBL31303791 | 0.71 | PRMT1 (0.79) | ALDH1A1HPGDMEN1KMT2APTGDR2 | |
| SCHEMBL3825168 | 0.71 | ALDH1A1 (0.64) | ALDH1A1HPGDPTGDR2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, ARG1 | ALDH1A1 787/4885HPGD 4263/4885MEN1 1037/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | ALDH1A1 800/4885HPGD 3468/4885MEN1 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.